Latigo Biotherapeutics (NASDAQ:LTGO) Rating Increased to Strong-Buy at Leerink Partners

Leerink Partners upgraded shares of Latigo Biotherapeutics (NASDAQ:LTGO) to a strong-buy rating in a research report report published on Tuesday,Zacks reports.

A number of other analysts have also recently issued reports on the company. Jefferies Financial Group started coverage on Latigo Biotherapeutics in a research report on Tuesday. They set a “buy” rating and a $50.00 price objective for the company. The Goldman Sachs Group assumed coverage on Latigo Biotherapeutics in a report on Tuesday. They set a “buy” rating and a $73.00 target price on the stock. Wall Street Zen upgraded Latigo Biotherapeutics to a “hold” rating in a report on Saturday, August 15th. Finally, Guggenheim began coverage on shares of Latigo Biotherapeutics in a report on Tuesday. They issued a “buy” rating and a $50.00 target price on the stock. Four equities research analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, Latigo Biotherapeutics has a consensus rating of “Strong Buy” and an average price target of $52.25.

Latigo Biotherapeutics Stock Up 1.1%

LTGO opened at $22.26 on Tuesday. Latigo Biotherapeutics has a 12-month low of $17.22 and a 12-month high of $25.93.

Insider Buying and Selling at Latigo Biotherapeutics

In related news, major shareholder Foresite Capital Management V, acquired 140,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were bought at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the acquisition, the insider owned 2,008,024 shares in the company, valued at $36,144,432. This trade represents a 7.49% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James B. Tananbaum bought 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the purchase, the director owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This trade represents a 7.49% increase in their position. The SEC filing for this purchase provides additional information.

Latigo Biotherapeutics News Roundup

Here are the key news stories impacting Latigo Biotherapeutics this week:

• Positive Sentiment: Multiple analyst upgrades: Leerink Partners, Jefferies Financial Group, Guggenheim, and Goldman Sachs each upgraded Latigo to “strong-buy.” The broad agreement among analysts may improve investor confidence and increase demand for LTGO shares.
• Positive Sentiment: Goldman Sachs initiates Buy rating: Analyst Salveen Richter cited Latigo’s differentiated non-opioid pain platform and Nav1.8 pipeline, along with the potential for significant peak sales. The thesis suggests investors see commercial opportunity in Latigo’s approach to pain treatment without opioids. Salveen Richter Initiates Buy on Latigo for Differentiated Non-Opioid Pain Platform and Nav1.8 Pipeline with Strong Peak Sales Potential
• Neutral Sentiment: Investor focus remains on the pipeline: Latigo’s valuation and future stock performance will likely depend on clinical progress, regulatory milestones, and whether its Nav1.8 candidates can demonstrate meaningful efficacy and safety in pain indications.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.